National Institutes of Health

CytoAgents is a clinical-stage biotechnology company focused on developing innovative pharmaceutical products for treating life-threatening symptoms associated with Cytokine Release Syndrome (CRS), an overreaction of the immune system causing systemic inflammation.

Behaivior LLC is a digital health company based in Pittsburgh, Pennsylvania, focused on predicting and preventing addiction relapses through innovative technology. Founded in 2017, Behaivior integrates wearable devices with machine learning algorithms to analyze real-time data from various physiological metrics, such as heart rate and skin temperature. The company’s platform, known as Recovery, employs this data to deliver timely interventions tailored to the needs of individuals in recovery. By utilizing a SaaS business model, Behaivior aims to democratize mental health recovery and support, assisting users in maintaining their wellness while enabling care providers to enhance their service delivery. Through its proactive approach, Behaivior seeks to improve mental health outcomes and reduce crisis events associated with addiction.

Integral Molecular, Inc. is a biotechnology company headquartered in Philadelphia, Pennsylvania, specializing in the development of innovative technologies for drug discovery targeting challenging diseases such as cancer, HIV, and arthritis. The company is particularly known for its Lipoparticle technology, which enhances the identification and optimization of drugs aimed at integral membrane proteins. With over 20 years of expertise in membrane proteins and antibodies, Integral Molecular has supported more than 400 pharmaceutical and biotechnology companies in their research, medication discovery, and vaccine development efforts. The company's solutions are integral to various stages of the drug discovery process, focusing on the development of chemical compounds and antibodies.

Advent Therapeutics specializes in developing therapies for micro-orphan indications, focusing on unmet medical needs in neonatal and pediatric patient populations. Based in Lumberville, Pennsylvania.

Behaivior LLC is a digital health company based in Pittsburgh, Pennsylvania, focused on predicting and preventing addiction relapses through innovative technology. Founded in 2017, Behaivior integrates wearable devices with machine learning algorithms to analyze real-time data from various physiological metrics, such as heart rate and skin temperature. The company’s platform, known as Recovery, employs this data to deliver timely interventions tailored to the needs of individuals in recovery. By utilizing a SaaS business model, Behaivior aims to democratize mental health recovery and support, assisting users in maintaining their wellness while enabling care providers to enhance their service delivery. Through its proactive approach, Behaivior seeks to improve mental health outcomes and reduce crisis events associated with addiction.

Founded in 1787, the University of Pittsburgh is a renowned research university offering professional medical education through its School of Medicine since 1886. It is ranked No. 24 worldwide and No. 9 among U.S. public universities.

Actuated Medical, Inc. is a medical device company based in Bellefonte, Pennsylvania, that focuses on designing, developing, and manufacturing innovative solutions for healthcare. Established in 2006, the company specializes in devices that facilitate occlusion clearing, tissue penetration, and MRI-guided surgical procedures. Their product line includes systems like TubeClear and NG-Clear, which are designed to clear clogs in feeding tubes, as well as devices for controlled tissue penetration, such as the GentleSharp Device and OsteoAccess System. Additionally, Actuated Medical offers MRI-compatible technologies, including direct drive piezoelectric ultrasonic motors that enhance diagnostic and surgical capabilities during imaging procedures. The company's commitment to improving patient care is reflected in their range of minimally invasive instruments and transdermal delivery systems. Actuated Medical was previously known as Piezo Resonance Innovations, Inc. before rebranding in September 2011.

Founded in 1891, Drexel is a comprehensive global research university ranked among the top 100 in the U.S., with approximately 26,000 students. Known for its leadership in experiential learning through co-op programs and a history of academic technology firsts, Drexel offers over 200 degree programs across 15 colleges and schools. It is committed to being civically engaged, with community partnerships integrated into service and academics.

CytoAgents is a clinical-stage biotechnology company focused on developing innovative pharmaceutical products for treating life-threatening symptoms associated with Cytokine Release Syndrome (CRS), an overreaction of the immune system causing systemic inflammation.

CytoAgents is a clinical-stage biotechnology company focused on developing innovative pharmaceutical products for treating life-threatening symptoms associated with Cytokine Release Syndrome (CRS), an overreaction of the immune system causing systemic inflammation.

Pennsylvania State University, founded in 1855, is Pennsylvania’s largest public university and the state’s only land‑grant institution. It operates 24 campuses across the Commonwealth, offering a broad range of undergraduate, graduate, and professional programs. The university emphasizes teaching, research, and public service, collaborating with partners to apply knowledge to community needs. Its specialized schools include the College of Medicine, Dickinson School of Law, World Campus, and Pennsylvania College of Technology. Students from around the world enroll, and many transfer from other Penn State campuses to the flagship University Park campus. The university’s governance is overseen by a board of trustees, and its assets are managed to support students, faculty, staff, and the broader community.

Behaivior LLC is a digital health company based in Pittsburgh, Pennsylvania, focused on predicting and preventing addiction relapses through innovative technology. Founded in 2017, Behaivior integrates wearable devices with machine learning algorithms to analyze real-time data from various physiological metrics, such as heart rate and skin temperature. The company’s platform, known as Recovery, employs this data to deliver timely interventions tailored to the needs of individuals in recovery. By utilizing a SaaS business model, Behaivior aims to democratize mental health recovery and support, assisting users in maintaining their wellness while enabling care providers to enhance their service delivery. Through its proactive approach, Behaivior seeks to improve mental health outcomes and reduce crisis events associated with addiction.

Windtree Therapeutics is a clinical-stage biotechnology company focused on developing novel surfactant therapies for respiratory diseases. Its proprietary technology platform includes KL4 surfactant, structurally similar to endogenous pulmonary surfactant, and novel drug-delivery technologies enabling noninvasive administration via aerosolization.

PhaseBio Pharmaceuticals is a clinical-stage biopharmaceutical company focused on developing novel therapies for cardiopulmonary diseases. Its lead product candidate, PB2452, is a reversal agent for the antiplatelet drug ticagrelor, intended to manage uncontrolled bleeding events or urgent surgeries. PhaseBio is also developing PB1046 for pulmonary arterial hypertension and PB6440 for resistant hypertension.

Windtree Therapeutics is a clinical-stage biotechnology company focused on developing novel surfactant therapies for respiratory diseases. Its proprietary technology platform includes KL4 surfactant, structurally similar to endogenous pulmonary surfactant, and novel drug-delivery technologies enabling noninvasive administration via aerosolization.

Windtree Therapeutics is a clinical-stage biotechnology company focused on developing novel surfactant therapies for respiratory diseases. Its proprietary technology platform includes KL4 surfactant, structurally similar to endogenous pulmonary surfactant, and novel drug-delivery technologies enabling noninvasive administration via aerosolization.

VenatoRx Pharmaceuticals is a biopharmaceutical company dedicated to discovering and developing novel anti-infective agents. Established in 2010, the company focuses on addressing multi-drug resistant bacterial infections, including those caused by MRSA, Pseudomonas spp., and Salmonella spp.

VenatoRx Pharmaceuticals is a biopharmaceutical company dedicated to discovering and developing novel anti-infective agents. Established in 2010, the company focuses on addressing multi-drug resistant bacterial infections, including those caused by MRSA, Pseudomonas spp., and Salmonella spp.

Trevena, Inc., founded in 2007 and headquartered in Chesterbrook, Pennsylvania, is a biopharmaceutical company dedicated to the development of innovative medicines for central nervous system (CNS) disorders. The company specializes in creating G protein-coupled receptor (GPCR) biased ligands, which aim to improve upon existing therapies by enhancing efficacy and reducing adverse effects. Trevena's pipeline includes several product candidates: Oliceridine injection, a mu-opioid receptor ligand completed Phase III trials for acute pain management; TRV250, a delta-opioid receptor agonist in Phase I study for migraine treatment; TRV734, a small molecule MOR ligand in Phase I study for acute and chronic pain; TRV027, currently in phase 2 clinical testing for the treatment of acute heart failure; and TRV045, an S1P modulator for managing chronic pain. Trevena has also collaborated with Imperial College London to evaluate Trv027 in Covid-19 patients.